A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases.
Transcriptional profiling of two isogenic models of transformation identifies a gene signature linking cancer with inflammatory and metabolic diseases. In accord with this common transcriptional program, many drugs used for treatment of diabetes and cardiovascular diseases inhibit transformation and tumor growth. Unexpectedly, lipid metabolism genes are important for transformation and are upregulated in cancer tissues. As in atherosclerosis, oxidized LDL and its receptor OLR1 activate the inflammatory pathway through NF-kappaB, leading to transformation. OLR1 is important for maintaining the transformed state in developmentally diverse cancer cell lines and for tumor growth, suggesting a molecular connection between cancer and atherosclerosis. We suggest that the interplay between this common transcriptional program and cell-type-specific factors gives rise to phenotypically disparate human diseases.
Hirsch
Heather A
HA
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Iliopoulos
Dimitrios
D
Joshi
Amita
A
Zhang
Yong
Y
Jaeger
Savina A
SA
Bulyk
Martha
M
Tsichlis
Philip N
PN
Shirley Liu
X
X
Struhl
Kevin
K
D050197:Atherosclerosis / Q000235:genetics*; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D003920:Diabetes Mellitus / Q000235:genetics; D020869:Gene Expression Profiling; D030342:Genetic Diseases, Inborn / Q000235:genetics*; D008040:Genetic Linkage; D014644:Genetic Variation; D006801:Humans; D007249:Inflammation / Q000235:genetics; D024821:Metabolic Syndrome / Q000235:genetics; D009369:Neoplasms / Q000235:genetics*; D009765:Obesity / Q000235:genetics; D051127:Scavenger Receptors, Class E / Q000235:genetics; D014158:Transcription, Genetic
C495137:OLR1 protein, human; D051127:Scavenger Receptors, Class E
Neuron. 1991 Aug;7(2):177-81
1873025
Biostatistics. 2003 Apr;4(2):249-64
12925520
Nucleic Acids Res. 2005 Nov 10;33(20):e175
16284200
Cancer Res. 1990 Sep 15;50(18):6075-86
1975513
Cancer Cell. 2007 Feb;11(2):119-32
17292824
Am J Clin Nutr. 2007 Sep;86(3):s836-42
18265477
FEBS Lett. 2008 Jan 9;582(1):81-9
18022388
Curr Opin Genet Dev. 2008 Feb;18(1):19-26
18440219
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21
11309499
Mol Cell Proteomics. 2006 Sep;5(9):1638-46
16844680
BMC Cancer. 2008 Feb 04;8:41
18248671
Cancer Res. 2003 May 15;63(10):2649-57
12750293
Science. 2005 Dec 9;310(5754):1642-6
16308421
Nat Biotechnol. 2006 Nov;24(11):1429-35
16998473
Physiol Genomics. 2007 Aug 20;30(3):335-41
17519360
J Clin Oncol. 2009 Jul 20;27(21):3437-44
19470939
Nat Rev Cancer. 2007 Apr;7(4):256-69
17384581
Int J Cancer. 2007 Aug 15;121(4):856-62
17397032
Nat Methods. 2008 Apr;5(4):347-53
18311145
Biostatistics. 2007 Jan;8(1):118-27
16632515
Proc Nutr Soc. 2008 May;67(2):128-45
18412987
Cancer Cell. 2008 Aug 12;14(2):156-65
18691550
Cell. 2009 Nov 13;139(4):693-706
19878981
Arterioscler Thromb Vasc Biol. 2003 Dec;23(12):2203-8
12958047
Nature. 1999 Jul 29;400(6743):464-8
10440377
Methods. 2003 Jul;30(3):256-68
12798140
Nature. 2008 Mar 27;452(7186):429-35
18344982
Oncogene. 2007 Dec 13;26(57):7894-903
17621275
Cell. 2008 Jun 27;133(7):1266-76
18585359
Am J Clin Nutr. 2007 Sep;86(3):s867-71
18265480
Cancer Res. 2006 Jun 15;66(12):5977-80
16778164
Nature. 2008 Jul 24;454(7203):436-44
18650914
Lancet. 2001 Feb 17;357(9255):539-45
11229684
Nat Rev Cancer. 2007 Oct;7(10):763-77
17882277
Science. 2009 Jun 26;324(5935):1720-3
19443739
Nature. 2006 May 25;441(7092):431-6
16724054
Nat Genet. 2008 May;40(5):499-507
18443585
Diabetologia. 2005 Sep;48(9):1776-83
16059715
Nat Genet. 2008 Feb;40(2):189-97
18193044
PLoS Genet. 2008 Mar 14;4(3):e1000036
18369455
Cancer Res. 2009 Oct 1;69(19):7507-11
19752085
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3329-35
14985505